Pfizer PFE is already laying the groundwork for what the pharmaceutical behemoth will look like when revenue from its outsized COVID-19 vaccine and treatment franchise begins to wane.

Researchers looked at how the vaccine affected patients' corneas - the clear front part of the eye that allows light to come ...

A new study suggests a potential link between the Pfizer COVID-19 vaccine and serious eye conditions like retinal vascular ...

Pfizer has boldly stepped into the burgeoning cannabis light market, giving the industry a serious growth spurt. The Cannabis Light Market is projected to grow at a 7.6% CAGR from 2025 to 2030, thanks ...

Dr. Philip Dormitzer, former global head of vaccine research and development at Pfizer, has been subpoenaed by the House Judiciary Committee as it investigates Pfizer’s alleged delay in the ...

Games Workshop has a new collectible coin coming in July and it's perfect for all you Horus Heresy Fans. Plus a Goremonger is up for grabs!

The U.S. Food and Drug Administration (FDA) has added new warnings to the Pfizer and Moderna COVID-19 vaccines about a rare heart condition that mostly affects young men.

Pfizer has earned a consensus rating of “Moderate Buy” from fifteen analysts, with only one calling it a “sell.” The average analyst price target is $29.17, despite recent coverage showing a cautious ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment analysis of PFE stock.

Pfizer's hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies, the U.S. drugmaker said on Thursday.